Testing company MBio Diagnostics stated on Monday that it plans to accelerate progress of its LightDeck platform to developing human host-response biomarker assays in identifying gravely ill or highly contagious individuals early in the disease cycle towards US FDA approval under an expanded scope contract with the US Defense Advanced Research Projects Agency (DARPA).
Since February 2018. MBio has partnered with DARPA on 'Point-of-care Monitoring of the Host-Pathogen Interaction During Infection'.
An additional USD1.5m in funding will allow MBio to augment its clinical and regulatory capabilities, in anticipation of the company seeking first FDA approvals for the LightDeck platform across military and other medical settings.
MBio's patented LightDeck platform incorporates low-cost, multiplexed cartridges with fluorescent readers and intuitive software, with the ability to measure more than 50 analytes in a single cartridge. Hence by measuring the specific blood biomarkers associated with the human immune response, it may be possible to identify infected individuals early before symptoms emerge, including COVID-19 disease symptoms.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT